PRF Technologies (PRFX) Amortization of Deferred Charges (2020)
PRF Technologies' (PRFX) quarterly Amortization of Deferred Charges came in at $366000.0 in Q3 2020, up 41.31% on a QoQ basis from $259000.0 in Q2 2020.
PRF Technologies (PRFX) Amortization of Deferred Charges (2020) Analysis & Trends
PRF Technologies (PRFX) has 1 years of Amortization of Deferred Charges data on file, last reported at $366000.0 in Q3 2020.
- Quarterly Amortization of Deferred Charges changed N/A year-over-year to $366000.0 in Q3 2020, while the trailing twelve-month figure through Dec 2020 was $987000.0 (changed N/A YoY) and the FY2020 annual result came in at $987000.0, up 82.44% from the prior year.
- Amortization of Deferred Charges rose to $366000.0 in Q3 2020, from $259000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $366000.0 in Q3 2020 to a low of $259000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | PRF Technologies | 647,973.00 | -3.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 366,000.00 |
| Sep 30, 2020 | 366,000.00 |
| Jun 30, 2020 | 259,000.00 |
| Jun 30, 2020 | 259,000.00 |
| Mar 31, 2020 | 362,000.00 |
| Mar 31, 2020 | 362,000.00 |